Analysts Set Novo Nordisk A/S (NVO) Price Target at $48.61

Share on StockTwits

Shares of Novo Nordisk A/S (NYSE:NVO) have been assigned a consensus rating of “Hold” from the eighteen brokerages that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $48.61.

NVO has been the subject of several analyst reports. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 29th. They issued an “outperform” rating for the company. Barclays reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 5th. Credit Suisse Group raised shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a report on Monday, April 29th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Friday, February 1st. They set an “equal weight” rating for the company. Finally, Handelsbanken downgraded shares of Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 price objective for the company. in a report on Monday, February 4th.

Shares of NYSE:NVO opened at $47.00 on Monday. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 0.07. Novo Nordisk A/S has a one year low of $41.23 and a one year high of $52.83. The firm has a market capitalization of $115.75 billion, a price-to-earnings ratio of 18.65, a PEG ratio of 2.12 and a beta of 0.56.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in Novo Nordisk A/S by 2.9% in the 1st quarter. Renaissance Technologies LLC now owns 21,344,916 shares of the company’s stock worth $1,116,553,000 after purchasing an additional 600,345 shares during the period. Loomis Sayles & Co. L P raised its position in Novo Nordisk A/S by 0.7% in the 1st quarter. Loomis Sayles & Co. L P now owns 20,886,188 shares of the company’s stock worth $1,092,557,000 after purchasing an additional 146,494 shares during the period. Fisher Asset Management LLC raised its position in Novo Nordisk A/S by 2.9% in the 4th quarter. Fisher Asset Management LLC now owns 14,202,935 shares of the company’s stock worth $654,329,000 after purchasing an additional 405,531 shares during the period. Folketrygdfondet raised its position in Novo Nordisk A/S by 0.7% in the 4th quarter. Folketrygdfondet now owns 5,732,591 shares of the company’s stock worth $264,100,000 after purchasing an additional 38,642 shares during the period. Finally, Northern Trust Corp raised its position in Novo Nordisk A/S by 0.5% in the 1st quarter. Northern Trust Corp now owns 2,330,848 shares of the company’s stock worth $121,926,000 after purchasing an additional 11,457 shares during the period. 7.04% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

See Also: Futures Contract

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Kimball Electronics  Stock Rating Upgraded by BidaskClub
Kimball Electronics Stock Rating Upgraded by BidaskClub
Peel Hunt Increases Hotel Chocolat Group  Price Target to GBX 365
Peel Hunt Increases Hotel Chocolat Group Price Target to GBX 365
Analyzing PAC BASIN SHIPP/ADR  & Scorpio Bulkers
Analyzing PAC BASIN SHIPP/ADR & Scorpio Bulkers
Lovesac Co  Given Consensus Rating of “Strong Buy” by Brokerages
Lovesac Co Given Consensus Rating of “Strong Buy” by Brokerages
Atara Biotherapeutics  Now Covered by Stifel Nicolaus
Atara Biotherapeutics Now Covered by Stifel Nicolaus
Critical Contrast: MFC Bancorp  and Bancolombia
Critical Contrast: MFC Bancorp and Bancolombia


© 2006-2019 Ticker Report